Jan. 03, 2026 9:45 AM ETAbbVie Inc. (ABBV) Stock, ABBV:CA StockDaniel Schönberger13.47K FollowersCommentsAbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold' rating.ABBV's growth is driven by Skyrizi and Rinvoq, offsetting Humira declines, with both drugs patent protected until 2033 and likely biosimilar-free until 2037.Despite raised guidance and a solid pipeline, ABBV trades at a historically high P/FCF of 20.8x, rendering it fairly valued based on DCF assumptions.High debt and dividend payouts constrain capital flexibility, but strong free cash flow and recession resilience support ABBV's investment case.hapabapa/iStock Editorial via Getty ImagesAfter underperforming for some time during the year, pharmaceutical companies actually caught up in the last three months of 2025 and the pharmaceutical sector outperformed the S&P 500 year-to-date. And among the pharmaceutical companies in theThis article was written byDaniel Schönberger13.47K FollowersMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small cap companies).My academic background is in sociology and I hold a Master’s Degree in Sociology (with main emphasis on organizational and economic sociology) and a Bachelor’s Degree in Sociology and History.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comments